Colorectal cancer (CRC) development and progression is associated with chronic inflammation. We have identified the MAPKactivated protein kinase 2 (MK2) pathway as a primary mediator of inflammation in CRC. MK2 signaling promotes production of proinflammatory cytokines IL-1b, IL-6 and TNF-a. These cytokines have been implicated in tumor growth, invasion and metastasis. For the first time, we investigate whether MK2 inhibition can improve outcome in two mouse models of CRC. In our azoxymethane/dextran sodium sulfate (AOM/DSS) model of colitis-associated CRC, MK2 inhibitor treatment eliminated murine tumor development. Using the implanted, syngeneic murine CRC cell line CT26, we observe significant tumor volume reduction following MK2 inhibition. Tumor cells treated with MK2 inhibitors produced 80% less IL-1b, IL-6 and TNF-a and demonstrated decreased invasion. Replenishment of downstream proinflammatory MK2-mediated cytokines (IL-1b, IL-6 and TNF-a) to tumors led to restoration of tumor proliferation and rapid tumor regrowth. These results demonstrate the importance of MK2 in driving proinflammatory cytokine production, its relevance to in vivo tumor proliferation and invasion. Inhibition of MK2 may represent an attractive therapeutic target to suppress tumor growth and progression in patients.
directly downstream of p38, is investigated as a potential therapeutic target. MK2 is phosphorylated by p38 and the p38-MK2 complex is transported to the nucleus, where MK2 induces the production of three characteristic inflammatory cytokines associated with CRC: IL-1b, IL-6 and TNF-a. [13] [14] [15] In contrast to p38, which activates a number of other pathways, MK2 inhibition targets far fewer pathways while decreasing production of tumor-promoting inflammation.
The MK2-mediated cytokines-IL-1b, IL-6 and TNF-aare strongly associated with inflammation-driven cancers, including CRC, and contribute to tumor growth and invasion. Signaling induced by these cytokines through their respective receptors leads to a cascade of proinflammatory activities that amplify inflammatory responses. In a mouse model of colitis, the severity of disease was greatly alleviated by blocking IL-1b release, and in a colitis-associated model, it reduces tumor burden and invasion. [16] [17] [18] IL-1b signaling in many cell types, including epithelial cells, fibroblasts and infiltrating immune cells, results in production of IL-6 and TNF-a. [19] [20] [21] [22] IL-6 levels are correlated with CRC development, tumor cell invasion, increased distant metastasis and decreased survival time. 23, 24 In mouse models of CRC, ablation of IL-6 reduces tumor burden and increases survival time, suggesting it is a critical tumor-promoting factor. 25 The combination of TNF-a and IL-6 produces a synergistic response in CRC that promotes proliferation, survival and further cytokine production. 26, 27 TNF-a is known to promote CRC tumor migration and invasion and facilitate protumorigenic immune cell infiltration. 28, 29 Blocking IL-1b, IL-6 and TNF-a, either with neutralizing antibodies or using knockout models has resulted in reduced tumor growth and invasion. [30] [31] [32] Our group has also shown that the majority of these cytokines produced during a model of colitis-associated CRC require MK2 signaling. 14 Here, we show that MK2 inhibition can drastically reduce growth in an IL-1b, IL-6 and TNF-a-dependent mechanism in two models of CRC. We demonstrated that IL-1b, IL-6 and TNF-a cytokines can activate the MK2 signaling pathway in a positive feedback loop. Replenishment of these cytokines to the tumor microenvironment during MK2 suppression restored tumor growth. Our work demonstrates the importance of these cytokines in mediating tumor growth and repopulation and suggest that blockade of MK2 signaling maybe an attractive target for managing CRC disease progression.
MATERIALS AND METHODS

Mice
Balb/c mice and C57/Bl6 mice were purchased from Harlan and bred in a pathogen free facility. All animal studies were approved by the University of New Mexico Health Sciences Center IACUC. Male and female mice were used at 6-10 weeks of age.
CT26 culture and tumors
CT26 cell were purchased from ATCC (Manassas, VA). Cells were cultured in complete RPMI with 5% FBS, 1% penicillin/ streptomycin and 1% L-glutamine. CT26 cells were treated for 48 hr before injection with either 50 lM of MK2 inhibitor PF364402 (Sigma Aldrich, St. Louis, MO) or DMSO vehicle control. Cells were injected at 10 5 in 50 ml of PBS into the flank of 6-8-week-old Balb/c mice. Some mice injected with cells exposed to MK2 inhibitors were treated with recombinant IL-1b, IL-6 and TNFa to replenish cytokine production in amounts of, 25 ng of IL-1b (Biolegend, San Diego, CA), 25 ng of TNFa (Biolegend) and 1 lg of IL-6 (Shenandoah, Warwick, PA). Treatments were administered 3 times/week from Day 2 until Day 13.
AOM/DSS model
Mice were treated with AOM/DSS as previously described. 14 In brief, 12.5 mg/kg of AOM (Sigma Aldrich, St. Louis, MO) was injected intraperitoneally (IP) into mice on Day 0. DSS (MP Biomedicals, MW 36,000-50,000) was added to drinking water at 2.5% on days 5 and 26 and at 2.0% at Day 47. DSS treatments were continued for five consecutive days. Beginning on Day 52, mice were injected three times per week for three weeks with vehicle control (DMSO in sterile DPBS), 2 mg/kg of PF364402 or MK2a inhibitor (Millipore, Billerica, MA) and euthanized at Day 80.
Cytokine arrays
8 mg (6 0.5 mg) of tumor tissues were incubated in complete RPMI media for 16 hr. Supernatants were analyzed by multiplex bead arrays (Millipore, Billerica, MA) for MK2 downstream cytokine levels (IL-1b, IL-6 and TNF-a), according to manufacturer's instructions and analyzed on a Luminex 200 machine.
Invasion assay
Tumor tissue was dissociated in HBSS with Ca1/Mg1, using a GentleMACS dissociator (Miltenyi Biotech, Cologne,
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Germany), in 25 U/ml of collagenase I, II and IV (Sigma Aldrich) incubated at 378C and 5% CO 2 for 20 min while rotating. After a second dissociation using the GentleMACS, 90 U/ml DNAse I (Worthington Biochemical, Worthington, MN) was added and tissues were incubated at 378C and 5% CO 2 for 20 min while rotating. Cells were filtered through a 40 lM filter, washed and resuspended in complete RPMI. Cells were plated in 96-well plates coated overnight with 10 lg/ml of recombinant human NS0-derived fibronectin (R&D Systems, Minneapolis, MN). Upon confluency, cells were incubated in serum-free RPMI for 24 hr, then scratched with a 10 ll pipette tip. Next, 50 ll of matrigel (Corning, Corning, NY) was added to each scratch. Wells were incubated with vehicle control, MK2 inhibitor (50 uM PF-364402) or MK2-downstream cytokines (10 ng/ml), IL-1b, TNFa and/or IL-6. Images were taken at initial scratch and 12 hr later. The mean scratch width (5 measurements per well) at 12 hr was compared to the mean scratch width at 0 hr to calculate the percent closure of the scratch.
Flow cytometry
Viability staining was performed via FACS staining with e660 viability dye (eBioscience, San Diego, CA) according to manufacturer's instructions. Samples were run on a Guava easyCyte 8HT flow cytometer (Millipore). Forward and side scatter gating was used and data were analyzed using GuavaSoft InCyte v3.1.1.
Western blot
Cells were treated for 30 min with 10 ng/ml of cytokines and lysed in RIPA buffer (Thermo Fisher Scientific, Rockford, IL). Protein was quantified using BCA protein assay (Thermo Fisher Scientific). 20 lg protein was loaded into each lane of a 10% bis-acrylamide gel. The gel was electrophoresed at 120v. Proteins were transferred to a membrane for 45 min at 100 V [voltage/mA]. The membrane was blocked overnight with 5% dry nonfat milk in TBS with 0.1% Tween-20. pMK2 antibody H66 (Santa Cruz Biotechnology, Santa Cruz, CA) was added at 1:1000 for 2 hr at room temperature. Rabbit anti-mouse-HRP (Thermo Fisher Scientific) was added at 1:10000 for 1 hr. Samples were visualized using SuperSignal West Femto substrate.
Proliferation assay 10 3 CT26 cells were seeded in a 96-well plate in complete RPMI. After 4 hr, wells were washed and incubated in serum-free RPMI containing 10 ng/ml of recombinant mouse IL-1b, IL-6, TNF-a or all three cytokines. Controls received an equal quantity of sterile PBS. After 96 hr, wells were tryspinized and samples were diluted in 50% trypan blue (Sigma) to exclude dead cells and cells were counted on a hemocytometer.
Real-time PCR
Tumor samples were homogenized with a bead-beater (Biospec, Bartlesville, OK) in Ribozol (Amresco, Solon, OH).
Manufacturer's protocol was used to extract RNA. RNA was quantified with a Nanodrop (Thermo Fisher Scientific). Only RNA with 260/280 readings of over 1.80 was used to ensure quality. The RT reaction mixture included random 2.5 lM hexamers, 500 lM dNTPs, 0.4 U/lL of the RNase inhibitors, 5.5 mM MgCl 2 , MultiScribe reverse transcriptase (3.125 U/ lL) and its buffer and 1 lg of cellular RNA. The RT step was performed according to the following protocol: 10 min at 258C, 60 min at 378C and 5 min at 958C. Obtained cDNA samples were stored at 2808C and used for the PCR reaction step. The PCR reaction mix was prepared using the Assayson-Demand TM gene expression assay mix (Applied Biosystems) for mouse b-actin, IL-1a, IL-1b, IL-6 and TNF-a (a 203 mix of unlabeled PCR primers and TaqMan V R MGB probe, FAM dye-labeled) and 2 lL of cDNA were added to the PCR reaction mix. The reaction was carried out according to the following protocol: 2 min at 508C, 10 min at 958C (1 cycle) and 15 s at 958C and 1 min at 608C (45 cycles) on Applied Biosystem's StepOnePlus instrument. The endpoint used in real-time PCR quantification, CT, was defined as the PCR cycle number that crossed the signal threshold. Quantification of cytokine gene expression was performed using the comparative CT method (Sequence Detector User Bulletin 2; Applied Biosystems) and reported as the fold change relative to the mouse housekeeping gene, b-actin mRNA.
Immunohistochemistry and imaging
Tumor samples were labeled by immunohistochemistry for pMK2 Thr334 (Cell Signaling Technology, Danvers, MA). Paraffin-embedded tissue sections (4 mm) were deparaffinized in citrisolv and rehydrated through a series of ethanol washes. Antigens were retrieved in 10 mM sodium citrate buffer plus 0.05% Tween-20 for 20 min at 958C. Sections were cooled in 3 washes of dH 2 O and endogenous peroxidases quenched in 3% H 2 O 2 for one hour at room temperature. Sections were then washed twice for 5 min in Trisbuffered saline plus 0.1% Tween-20 (TBST) and blocked in 2.5% normal horse serum (Vector Laboratories, Burlingame, CA) for 1 hr at room temperature. Sections were incubated in primary antibody in a humidified chamber at 48C overnight. The following day, sections were washed twice for 5 min in TBST and incubated in biotinylated secondary antibody (Vector Laboratories) for 1 hr at room temperature, followed by 23 5 min washes in TBST, 13 5 min wash in PBS and 1 hr incubation in avidin-biotin complex (ABC; Vector Laboratories). Sections were washed once for 5 min in TBST, stained with DAB, and washed once for 5 min in dH 2 O. Tissue was counterstained with Harris hematoxylin solution, dehydrated and coverslipped. Sections were imaged with a Zeiss AxioCamHR digital color camera mounted atop a Zeiss AxioSkop 2 MOT upright microscope (Zeiss, Oberkochen, Germany). Images were generated in the University of New Mexico Cancer Center Fluorescence Microscopy Shared Resource.
Statistics
All results are expressed as the mean 6 standard error of the mean. Differences between means were evaluated by student's t test or one-way ANOVA in GraphPad Prism 5. p values of 0.05 or less were considered statistically significant.
RESULTS
MK2 inhibition reduces CRC tumor growth
We previously showed that MK2 signaling was required for CRC development in the AOM/DSS model. 14 To investigate the importance of MK2 pathway in CRC tumor progression, the syngeneic CT26 model was examined. Sections from CT26 tumors demonstrated constitutively activated phosphorylated MK2 by immunohistochemistry (Fig. 1a) . To prevent MK2 signaling, CT26 cells were treated with the specific MK2 inhibitor PF3644022 for 48 hours before injection into the mice. At Day 13, the mean tumor volume for vehicle control treated cells was 113 mm 3 , while the mean tumor volume from cells treated with MK2 inhibitor was 49 mm 3 ( Fig. 1b) . Remarkably, the reduction in growth was proportional to Day 19 where control tumors had a mean tumor volume of 2260 mm 3 and those treated with MK2 inhibitor had a mean of 957 mm 3 ( Fig. 1c) . At both d13 and d19, the relative volume of the tumors from tumor cells treated with MK2 inhibitor was an average of 60% decreased compared to control tumor size (Fig. 1d) . No acceleration in growth was observed at the later timepoint, suggesting that MK2 inhibition is a profound and lasting obstruction to tumor growth. A representative picture of tumor size is shown in Figure 1e . Cells treated with MK2 inhibitors did not exhibit a decrease in viability when stained with viability dye (Fig. 1f) , suggesting another mechanism by which MK2 inhibition reduces tumor growth beyond tumor cell toxicity. A reduction in tumor size was also observed when CT26 cells were transfected with MK2 shRNA compared to control shRNA and injected into Balb/c mice ( Supporting Information, Fig. S1 ).
To further examine the potential for MK2 inhibition to decrease tumor growth, the AOM/DSS model of CRC was also examined. Previously, our group found tumors developed by Day 52 in this model, 33 thus MK2 inhibitor treatments were administered starting at Day 52, three times a week for 3 weeks (Fig. 2a) . For this model, we not only tested the MK2 inhibitor PF364402, but also tested a second inhibitor, MK2a, to ensure specificity of results. Control mice had an mean of 2.6 neoplasms, while mice treated with MK2 inhibitors had a mean of <1 neoplasm per mouse. The majority of both of the MK2 inhibitor groups were completely neoplasm-free in these groups (Fig. 2b) . These results, in combination with the observed decrease in tumor growth in the CT26 model, suggest that MK2 activity is critical for tumor growth in multiple models of CRC, and that two MK2 inhibitors lead to similar results in decreasing tumor growth.
MK2 inhibition reduces proinflammatory cytokines associated with CRC
As the MK2 pathway is responsible for proinflammatory cytokine production, we examined the impact of MK2 inhibition on cytokine production in organ culture supernatants from the two models of CRC. In the CT26 model, MK2 inhibition led to dramatically reduced levels of IL-1b, IL-6 and TNF-a when compared with control tumors (Figs. 3a-3c) . Similar results were seen with tumors developed from cells transfected with MK2 shRNA compared to control shRNA ( Supporting Information, Fig. S2 ). As numerous cell types comprise the tumor microenvironment including tumor cells, infiltrating immune cells and stroma, the specific role of tumor cells in cytokine production was examined by culturing tumor cells. Tumors were dissociated and cultured in fibronectin coated wells to enhance attachment. Purity of tumor cells in culture was confirmed by flow cytometry. These cells produced IL-6 and TNF-a, but the cells from tumors that had been treated with MK2 inhibitors before injection produced very little IL-6 and undetectable levels of TNF-a (Figs. 3d and 3e ). Tumor cells did not produce detectable levels of IL-1b, suggesting that other cells in the tumor microenvironment are the source of IL-1b in this model. Cytokines were also measured in the AOM/DSS model colon tissues after therapeutic MK2 inhibition. In this model, colon tissues from mice exposed to MK2 inhibitors showed no visible signs of inflammation, redness or thickening as seen in control mice (data not shown). Similar to the CT26 model, AOM/DSS treated mice administered MK2 inhibitors showed drastically reduced IL-1b and IL-6 and undetectable levels of TNF-a (Figs. 3f-3h) . Similar results were seen with the MK2a inhibitor to support our results with the PF364402 inhibitor. These data suggest a long-lasting anti-inflammatory phenotype upon MK2 inhibition and support the central role of MK2 in CRC-related inflammation.
MK2 downstream cytokines induce proliferation and invasion of tumor cells
As MK2 inhibition led to both decreased tumor burden and reduced downstream cytokine production, the impact of MK2 inhibitors and these cytokines on tumor cell proliferation was examined. When cells were treated with 10 lg/ml of IL-1b, IL-6 or TNF-a, drastic increases in cell numbers were observed at 96 hr in example images (Fig. 4a) . MK2 inhibitor treatment did not directly reduce proliferation (Fig. 4b) , but when cells were treated with 10 lg/ml of IL-1b, IL-6 or TNF-a, drastic increases in cell numbers were observed at 96 hours upon counting cells. Furthermore, combining all three cytokines led to a synergistic effect on control cells and had a similar effect on cells treated with MK2 inhibitor. These data support the role of each of the MK2-downstream cytokines in promoting tumor cell proliferation, thus In organ culture supernatants, cytokine treatment increased the MK2i tumor production of (e) IL-1b, (f) IL-6 and (g) TNF-a. Increases were seen in mRNA levels for (h) IL-1b, (i) IL-6 and (j) TNF-a were also seen. N 5 10 *p < 0.05, **p < 0.01, ***p < 0.005.
suggesting a mechanism by which the MK2 pathway promotes tumor growth.
In addition to proliferation, MK2-downstream cytokines may drive invasion of tumor cells in some models. [34] [35] [36] Thus, the role of these cytokines in CT26 invasion was analyzed in scratch-wound assays where matrigel was added to the scratched wound. Scratches were measured over time and MK2 inhibition was found to drastically reduce the speed of regrowth and invasion through matrigel. As seen in example images in Figure 5a , CT26 cells invaded the matrigel-filled scratch by forming protrusions over time, which bridged the scratch within 72 hours. In contrast, wells treated with MK2 inhibitor developed very few protrusions and demonstrated vastly decreased invasion (Fig. 5b) . To assess the impact of MK2-downstream cytokines on invasion, a mixture of IL-1b, IL-6 and TNF-a significantly increased invasion (Fig. 5c) . Furthermore, addition of these cytokines to cells treated with MK2 inhibitor rescued the effects of the MK2 inhibitor on invasion. As MK2 inhibition does not decrease viability of tumor cells, the ability of cytokines downstream of MK2 to restore proliferation and invasion of cells treated with MK2 inhibitor suggests the mechanism by which MK2 signaling promotes colorectal tumors.
Addition of MK2 downstream cytokines to tumors increases tumor size and cytokine production
To further investigate the mechanism by which the MK2 downstream cytokines promote chronic inflammation and tumor growth, the effects of MK2-induced cytokines on MK2 phosphorylation were examined. CT26 cells were serum starved to normalize signaling activity. Cytokines were added to some wells to assess MK2 phosphorylation. Addition of IL-1b, IL-6 or TNF-a led to MK2 phosphorylation, indicating these downstream cytokines may act in an autocrine manner on MK2 activity in tumor cells (Fig. 6a) .
Given the effects of MK2 downstream cytokines on tumor cell proliferation and invasion, and their ability to activate MK2, the effects of these cytokines on tumors were examined in vivo. Control CT26 cells and cells treated with MK2 inhibitor were injected into mice and a cocktail of recombinant IL-1b, IL-6 and TNF-a (in similar amounts as were produced by tumors in Fig. 3 ) was administered intratumorally to CT26 tumors beginning at Day 2 and continuing three times per week. Tumors formed from CT26 cells treated with MK2 inhibitor grew to the size of control tumors when IL1b, IL-6 and TNF-a concentrations were replenished to control levels using recombinant proteins (Figs. 6b and 6c) . Control tumors treated with cytokines also increased in size compared to PBS controls. The mean volume of vehicle control tumors approximately doubled compared to the sixfold increase in size observed in tumors from cells treated with MK2 inhibitor (Fig. 6d) . This difference observed in increases between control and MK2 inhibitor groups may be due to saturation of cytokine signaling, and limits to cell proliferation capacity. These data suggest that the drastic decrease in MK2-downstream cytokines was responsible for the decrease in tumor size seen with MK2 inhibition.
To confirm cytokine replenishment in MK2 inhibitor-treated tumors, organ culture supernatants were examined. Figures 6e-6g indicate that MK2-downstream cytokines were effectively replenished by cytokine treatment. The effects of the recombinant cytokines on mRNA levels were measured to further confirm the MK2/cytokine feedback loop. RNA levels for IL-1b, IL-6 and TNF-a were increased in tumors where cells were treated with MK2 inhibitor and then treated with a cocktail of recombinant IL-1b, IL-6 and TNF-a (Figs. 6h-6j) . Direct addition of MK2-downstream cytokines to tumors was able to restore MK2 activity, activate proinflammatory cytokine production and restore tumor size. These data support the critical role of inflammation in CRC growth, mediated through MK2.
DISCUSSION
MK2 is a growing target of interest in multiple cancers because it mediates three key inflammatory cytokines, IL-1b, IL-6 and TNF-a. Data presented here show that these cytokines are primary mediators of tumor growth in both colitisassociated and spontaneous models of CRC. Others have undertaken studies to block these cytokines individually in tumor models with some success. For example, IL-1b blockade in an AOM/DSS model reduced tumor number by approximately half, but all mice developed tumors. 18 IL-6 was shown to contribute to tumor burden in a colorectal cancer xenograft model, and inhibition of IL-6 reduced tumor weight by 50%. 21 Anti-TNF-a therapy reduced the number of colon tumors in obese mice by 50%, and volume by approximately two-thirds in another study. 27 The same trend has been observed in a model of skin cancer, where TNF-a 2/2 mice developed fewer tumors than wildtype mice, but more than MK2 2/2 . 37 Here we show that MK2 inhibition in the AOM/DSS model led to tumor regression with no tumors in 11/14 mice. MK2 inhibitor treatment showed a greater reduction in tumor burden compared to studies with single-cytokine targeted therapies, thus suggesting its potential as a therapeutic target.
MK2 activity initiates an autocrine loop with IL-1b, IL-6 and TNF-a, each having the ability to lead to phosphorylation of MK2 in tumor cells (Fig. 6a) . As cytokines are produced, they can signal in a paracrine manner, activating more MK2 signaling and in turn more cytokine production. Chronic inflammation is a critical component of the tumor microenvironment that promotes tumor progression. In our colitisassociated model, no gross signs of inflammation were observed in the colons of mice treated with MK2 inhibitor. Furthermore, in tumors initiated from CT26 cells, pretreatment of cells resulted in persistent reduction in cytokine production both from isolated tumor cells and from whole tumor supernatants. Interruption of the MK2-cytokine feedback loop appeared to have long-term effects as cells pretreated with MK2 inhibitors continued to have reduced cytokine production 13 days after injection into mice (Figs. 3a-3c ).
In the CT26 cell injection model, treatment of these cells with MK2 inhibitor led to a 60% reduction in tumor volume at both 13 and 19 days after injection (Figs. 1a and 1c) . As inflammatory cytokines are mediators of tumor growth, MK2-downstream cytokines were added back into tumors in biologically relevant amounts in the range of levels measured in organ culture supernatants. Adding these cytokines back to tumors restored tumor growth to that of control tumors (Fig. 6b) . These findings indicate that the MK2 feedback loop can be restored by reintroducing inflammatory signaling. The consequence of restoring MK2-mediated cytokines allows these tumors to perpetuate a positive feedback loop facilitating rapid tumor growth. However, tumors exposed to MK2 inhibitor without restoring inflammation remained proportionally smaller than control tumors suggesting a lasting effect of MK2 inhibition.
One explanation for a reduced tumor burden in MK2-inhibited tumors compared to any single cytokine pathway blockade is crosstalk between inflammatory pathways. Inflammasome activation is essential for IL-1b production. The inflammasome can be activated by microbial changes during colitis, but also by TNF-a in a sterile manner. 38, 39 In turn, IL-1b can drive IL-6 production. Thus, blocking TNF-a can reduce IL-1b and IL-6 levels, but if the inflammasome is activated by invasion of microbiota through the damaged epithelium, there is a backup pathway that results in IL-1b and IL-6 production. Therefore, inhibition of MK2 adds additional feedback checkpoints, where both IL-1b and IL-6 would be inhibited.
MK2 activity promotes not only proinflammatory pathways, but other pathways that control cell cycle. MK2 2/2 mice have shown resistance to skin cancer, where they grew fewer tumors than wild-type mice. Part of this reduction is likely due to reduced TNF-a production as TNF-a 2/2 animals exhibit reduced tumor size and changes in cell cycle and DNA repair signaling. 37 In addition to inflammation, MK2 substrates include cell cycle proteins, DNA damage repair and proteins associated with epithelial-to-mesenchymal transition. [40] [41] [42] may have a significant effect on one or more of these areas within CRC so further investigation is warranted. MK2 also participates in cell cycle/proliferation pathways, which may support its importance in survival and therefore could be a potential therapeutic target of interest. 43 In glioblastoma cells, MK2 activity regulates the protumor protein Khsrp and induces secretion of IL-6, which promotes tumor growth and invasion in glioblastoma. 44, 45 MK2 knockout also significantly prevented tumor development in a model of skin cancer, and increased apoptosis in leukemia cells. 37, 46 MK2 inhibition may also be a potential target for combination therapies. Although we showed MK2 inhibition does not directly induce tumor cell apoptosis, inhibiting both MK2 along with the cell cycle promoter Chk1 results in tumor cytotoxicity across multiple therapy-resistant cell lines. 43 In a model of non-small-cell lung cancer, MK2 inhibition sensitized p53-deficient tumors to cisplatin treatment. 47 Many chemotherapeutics, including those commonly used in CRC, promote inflammation, 48 further suggesting that MK2 inhibition could counteract tumor promoting inflammation during traditional chemotherapy approaches. Specifically, chemoresistance has been directly linked with IL-6 and IL-1. [49] [50] [51] It is possible that the anti-inflammatory effects of MK2 inhibition could help prevent chemoresistant subpopulations developing in CRC. Taken together, our data demonstrates for the first time the role of MK2 in driving CRC tumor growth, the effect of inflammatory tumor cytokine production on maintaining tumor proliferation and how MK2 blockade can break this inflammatory feedback loop leading to substantive inhibition of CRC. Therefore, consideration of therapeutic studies targeting the MK2 pathway in inflammatory tumors should be considered.
